Tibolone;La Tibolone

Presse Medicale

Volumn 31, Issue 28, 2002, Pages 1314-1322

  Jamin, Christian ^a   Poncelet, Christophe ^a   Madelenat, Patrick ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHOLESTEROL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TIBOLONE; TRIACYLGLYCEROL;

BLEEDING; BONE; BRAIN; BREAST; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIUM; ESTROGEN DEFICIENCY; FEMALE; FIBRINOLYSIS; FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIVER; MASTALGIA; MENOPAUSE; METABOLISM; METABOLITE; MUSCLE; OSTEOLYSIS; REVIEW; SIDE EFFECT; UROGENITAL SYSTEM; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANIMALS; BLOOD COAGULATION; BREAST; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; LIPID METABOLISM; LIPIDS; MEDROGESTONE; MENOPAUSE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PLACEBOS; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RABBITS; RATS; RISK FACTORS; TIME FACTORS;

EID: 0037037285     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Helmond FA. Dose-response analysis of effects of tibolone on climateric symptoms in highly symptomatic subjects with at least seven hot flushes and sweats per day. 9th International Menopause Symposium, Yokohama, 1999.
2. Crona N, Samsioe G, Lindbergh UB, Silfverstolpe G. Treatment of climacteric complaints with ORG OD 14: A comparative study with oestradiol valerate and placebo. Maturitas 1988; 9: 303-8.
3. Crook D. Tibolone lowers HDL concentrations but does not impair cholesterol efflux from cells. Eu Menop Androp Soc, Copenhague, 2000.
4. Egarter C, Huber J, Leikermoser R, Haidbauer R, Pusch H, Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996; 23: 55-62.
5. Hammar M, Christau S, Nathorst-Boos J, Rud T, Horber FF. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Brit J Obstet Gynaecol 1998; 105: 904-11.
6. Ginsburg J. Clinical experience with tibolone (Livial®) over 8 years. Maturitas 1995; 71-6.
7. Morris E P, Wilson POG, Robinson J, Rymer JM. Long term effects of tibolone on the genital tract in postmenopausal women. Brit J Obstet Gynaecol 1999; 106: 954-9.
8. Hannover Bjarnason N, Bjarnason K, Haarbo J, Coelingh Bennink HJT, Chistiansen C. Tibolone: Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2419-22.
9. Studd J, Arnala I, Kicovic PM, Zamblera D, Kroger H. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92: 574-9.
10. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991; 13: 155-62.
11. Rymer J. Livial® prevents postmenopausal bone loss - Eight-year follow-up. 9th International Menopause Symposium, Yokohama 1999.
12. Prevelic GM, Bartram C, Wood J, Okolo S, Ginsburg I. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 1996; 10: 413-20.
13. Lippuner K, Haenggi W, Birkhauser MH, Casez JP, Jaeger PH. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. J Bone Miner Res 1997; 12: 806-12.
14. Grodstein F, Stampfer M.J. The epidemiology of coronary heart disease and estrogen replacement in post-menopausal women. Progr Cardiovasc Dis 1995; 38: 199-210.
15. Jamin C. THS et bénéfice coronarien: Mythe ou réalité. Contracept Fertil Sex 1997; 25: 793-7.
16. Matthews KA. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143: 971-8.
17. Zandberg M. The atheroprotective effects of tibolone and its metabolites. 9th International Menopause Symposium, Yokohama, 1999.
18. Benedek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women. Maturitas 1987; 1: 25-33.
19. Mendoza N. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17b-estradiol for hormonal replacement therapy in women with surgical menopause. Maturitas 2000; 37:37-43.
20. Milner MH. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996; 87: 593-9.
21. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated by Org OD 14. Maturitas 1987; 1: 67-72.
22. Scherwin BB, Gelfand MM. Androgen enhances sexual motivation in females. A prospective crossover study of sex steroïd administration in surgical menopause. Psychosom Med 1985; 47: 339-51.
23. Rymer J, Chapmand MG, Fogelman I, Wilson POG. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994; 18: 127-33
24. Palacios S, Menendez C, Jurado AR, Castang R, Vargas JC. Changes in sex behaviour after menopause: Effects of tibolone. Maturitas 1995; 22: 155-61.
25. Nathorst-Boos J, Hammar M. Effect on sexual life - A comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997; 26: 15-20.
26. Castelo-Branco C, Vicente JJ, Figueras F, Sanuan A, Martinez de Osaba MJ. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000; 34: 161-8.
27. Henderson VW. Hormonothérapie substitutive et maladie d'Alzheimer. Reproduc Hum Horm 1998; 11: 241-6.
28. Valdivia I. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clinic Drug Investig 2000; 20: 101-7.
29. Kloossterboer HJ. Effects of Progestagens and Org OD 14 in in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 1994; 49: 311-18.